Diethylstilbestrol

From WikiMD's WELLNESSPEDIA

(Redirected from Neo-Oestranol 1)

Diethylstilbestrol structure
File:Diethylstilbestrol molecule ball.png
Diethylstilbestrol 3-D balls

Diethylstilbestrol (DES) is a synthetic, nonsteroidal estrogen that was previously used in medical treatments and as an additive in livestock and poultry feed. It has a complex history marked by therapeutic uses and later, significant health concerns.

History[edit]

Diethylstilbestrol was first synthesized in 1938. During the mid-20th century, DES was commonly prescribed for a variety of conditions in women, ranging from suppressing lactation to preventing miscarriages. Its use in animal feed aimed to promote growth and improve meat production.

Medical Uses[edit]

The primary medical application of DES was to prevent complications during pregnancy. It was believed that by supplementing estrogen, miscarriages, and premature deliveries could be minimized. However, subsequent research showed that DES was ineffective for this purpose.

Use in Livestock and Poultry[edit]

In agriculture, DES was used as a growth-promoting agent in livestock and poultry feed. The estrogenic properties of DES were believed to enhance meat production by accelerating weight gain and promoting the deposition of certain fats.

Health Concerns and Bans[edit]

By the early 1970s, it became evident that prenatal exposure to DES increased the risk of a rare form of vaginal cancer known as clear cell adenocarcinoma in daughters of the women who took DES. Further studies also revealed that DES was associated with increased risks of breast cancer, infertility, and other health issues in both the women who took it and their offspring.

Consequently, the FDA in the USA and its counterparts in many other countries banned the use of DES in pregnant women. The use of DES in animal feed was also phased out.

Current Status[edit]

The use of DES in both human medicine and animal agriculture has significantly diminished due to associated health risks. Today, DES serves mainly as a case study in pharmaceutical regulation and the importance of rigorous drug testing.

See Also[edit]




Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.